



## Table of contents


1. **Figure S1:** FACS analysis of commercial exosomes.
2. **Figure S2:** Western Blot analysis of commercial exosomes.
3. **Figure S3:** Hydrodynamic size distribution profiles of different exosomes used.
4. **Figure S4.** Comparison of capture antibodies by LFIA.




**Figure S1.** FACS analysis of CD9, CD63 and CD81 expression on plasma (HBM-PEP) and urine (HBM-PEU) purified exosomes. Green line, isotype control. Purple line, the indicated antibody.



**Figure S2.** Western Blot analysis of CD63, CD81 and CD9 expression on 20 µg of exosomes purified from plasma (HBM-PEP) and urine (HBM-PEU) using respectively antibodies anti-CD63, anti-CD81 and anti-CD9 (HansaBioMed, Tallinn, Estonia).



**Figure S3.** Hydrodynamic size distribution profiles of different types of exosomes (Ma-Mel- 86c, plasma and urine exosomes from healthy donors). The graph shows one reading representative of three. Data shown an average size of 311 nm (PDI=0.072) and 174 nm (PDI=0.270) for exosomes purified from plasma and urine of healthy donors (HBM), respectively.



**Figure S4.** Comparison of capture antibodies by LFIA using  $1.78 \times 10^7$  exosomes/ $\mu\text{L}$  of the melanoma cell line Ma-Mel-86c. All the assays were performed in triplicate and were scanned in grey scale and optical densities measured using ImageJ 1.48v software. Capture mAb: A) Anti-CD81. B) Anti-CD9. C) Blend of anti-CD9 and anti-CD81. Mixtures of antibodies in the test line did not improve the results obtained when anti-CD9 alone was used as capture antibody.